Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells

American Journal of Obstetrics and Gynecology

Volumn 202, Issue 4, 2010, Pages 371.e1-371.e8

  Loar, Paul ^a   Wahl, Heather ^a   Kshirsagar, Malti ^a   Gossner, Gabrielle ^a   Griffith, Kent ^a   Liu, J Rebecca ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

apoptosis; glycolysis; ovarian carcinoma

Indexed keywords

ADENOSINE TRIPHOSPHATE; CISPLATIN; DEOXYGLUCOSE; GLUCOSE TRANSPORTER 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 77949911987     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.10.883     Document Type: Article

References (29)

1. Pelicano H., Martin D.S., Xu R.H., and Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 25 (2006) 4633-4646
2. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
3. Semenza G.L., Artemov D., Bedi A., et al. The metabolism of tumours: 70 years later. Novartis Found Symp 240 (2001) 251-264
4. Zhang X.D., Deslandes E., Villedieu M., et al. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 26 (2006) 3561-3566
5. Maschek G., Savaraj N., Priebe W., et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64 (2004) 31-34
6. Chiang G.G., and Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol Med 13 (2007) 433-442
7. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell 4 (2003) 343-348
8. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6 (2006) 729-734
9. Kalir T., Wang B.Y., Goldfischer M., et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer 94 (2002) 1078-1082
10. Altomare D.A., Wang H.Q., Skele K.L., et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23 (2004) 5853-5857
11. Gossner G., Choi M., Tan L., et al. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol 105 (2007) 23-30
12. Wahl H., Tan L., Griffith K., Choi M., and Liu J.R. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 105 (2007) 104-112
13. Barthel A., Okino S.T., Liao J., et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem 274 (1999) 20281-20286
14. Feng Z., Zhang H., Levine A.J., and Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 102 (2005) 8204-8209
15. Brown E.J., Beal P.A., Keith C.T., Chen J., Shin T.B., and Schreiber S.L. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377 (1995) 441-446
16. Mabuchi S., Altomare D.A., Connolly D.C., et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67 (2007) 2408-2413
17. Search of "deoxyglucose". http://clinicaltrials.gov/ct2/results?intr=%22Deoxyglucose%22 Accessed March 1, 2008
18. Hajra K.M., and Liu J.R. Apoptosome dysfunction in human cancer. Apoptosis 9 (2004) 691-704
19. Ha H.C., and Snyder S.H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A 96 (1999) 13978-13982
20. Jerusalem G., Hustinx R., Beguin Y., and Fillet G. PET scan imaging in oncology. Eur J Cancer l 39 (2003) 1525-1534
21. Mohanti B.K., Rath G.K., Anantha N., et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 35 (1996) 103-111
22. Jin S., DiPaola R.S., Mathew R., and White E. Metabolic catastrophe as a means to cancer cell death. J Cell Sci 120 (2007) 379-383
23. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol Med 11 (2005) 353-361
24. Elstrom R.L., Bauer D.E., Buzzai M., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64 (2004) 3892-3899
25. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
26. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
27. Takeuchi H., Kondo Y., Fujiwara K., et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65 (2005) 3336-3346
28. Kim K.W., Mutter R.W., Cao C., et al. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem 281 (2006) 36883-36890
29. Yamada M., Tomida A., Yun J., et al. Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemother Pharmacol 44 (1999) 59-64